Background/aims: Dose-finding trials can be conducted such that patients are first stratified into multiple risk groups before doses are allocated. The risk groups are often completely ordered in that, for a fixed dose, the probability of toxicity is monotonically increasing across groups. In some trials, the groups are only partially ordered. For example, one of several groups in a trial may be known to have the least risk of toxicity for a given dose, but the ordering of the risk among the remaining groups may not be known. The aim of the article is to introduce a method for designing dosefinding trials of cytotoxic agents in completely or partially ordered groups of patients. Methods: This article presents a method for dose-finding that combines previously proposed mathematical models, augmented with results using order restricted inference. The resulting method is computationally convenient and allows for dose-finding in trials with completely or partially ordered groups. Extensive simulations are done to evaluate the performance of the method, using randomly generated dose-toxicity curves where, within each group, the risk of toxicity is an increasing function of dose. Results: Our simulations show that the hybrid method, in which order-restricted estimation is applied to parameters of a parsimonious mathematical model, gives results that are similar to previously proposed methods for completely ordered groups. Our method generalizes to a wide range of partial orders among the groups. Conclusion: The problem of dose-finding in partially ordered groups has not been extensively studied in the statistical literature. The proposed method is computationally feasible, and provides a potential solution to the design of dosefinding studies in completely or partially ordered groups.
Introduction
Yuan and Chappell 1 proposed several methods for dose-finding trials in which patients are first stratified into multiple risk groups. The risk groups are completely ordered in the sense of Robertson et al. 2 in that for a fixed dose, the probability of a dose-limiting toxicity is monotonically increasing across groups. There are several examples of such trials in the literature, including Ramanathan et al. 3 and LoRusso et al., 4 who stratify patients into ''none,''''mild,''''moderate,'' or ''severe'' liver dysfunction at baseline. Leal et al. 5 divide patients into groups defined by increasing renal dysfunction at baseline based on a measure of 24-h creatinine clearance. Kim et al. 6 genotyped UGT1A1 *28 and *6, and defined patient cohorts by the number of defective alleles: 0, 1, or 2. Satoh et al. 7 also investigated dose-finding with groups defined by UGT1A1 genotypes. In this study, patients were divided into three groups according to wild-type (*1 *1 ), heterozygous (*28, *1, *6, *1 ), or homozygous (*28, *28, *6*6, *28, *6 ). Each of these studies is an example of ''completely ordered'' groups. For a given dose of the agent, we would anticipate a greater chance that a patient with a greater degree of organ dysfunction at baseline or a greater number of defective alleles would experience a dose-limiting toxicity (DLT).
There are fewer published examples of partially ordered groups, but these would arise naturally when one of K groups in a trials may be known to have the greatest risk of toxicity for a given dose, but the ordering of the risk among the remaining K À 1 groups may not be known. Innocenti et al. provide an example of this in a genotype-directed dose-finding study of irinotecan. 8 Based on the observation that the risk of severe neutropenia with irinotecan is related in part to UGT1A1 *28, Innocenti et al. 8 sought to identify the maximum tolerated dose (MTD) of irinotecan in patients with advanced solid tumors stratified by the *1/*1, *1/*28, and *28/*28 genotypes. The greatest risk of a DLT was expected to be in patients with the *28/ *28 genotype. In other trials, patients might be stratified into groups based on the presence or absence of two genetic mutations. For a fixed dose of an agent, those without either mutation might have the least risk and those with the both mutations might have the greatest risk. The ordering between the probability of toxicity at a given dose for patients with one mutation might not be known.
To our knowledge, the only paper that addresses dose-finding in more than two groups is Yuan and Chappell, 1 although there have been several methods proposed for dose-finding in two groups of patients. O'Quigley et al. introduced the two-sample continual reassessment method, which allowed for the identification of the appropriate MTD's for two groups simultaneously. 9 O'Quigley and Paoletti 10 proposed a twoparameter continual reassessment method for ordered groups that utilizes known differences between the groups. Ivanova and Wang 11 incorporate isotonic regression estimates into designs for ordered groups that take into account both toxicity and efficacy endpoints. Wages et al. 12 describe the design of a dosefinding trial that explicitly uses the known ordering in the probabilities associated with ''good'' and ''poor'' prognosis patients. Their design is based on the shift model 13, 14 that generalizes the continual reassessment method to two ordered groups. Conaway and Wages 15 propose two methods based on the estimation method of Hwang and Peddada. 16 In this article, we first propose a simple modification of the ''isotonic regression continual reassessment method'' proposed by Yuan and Chappell 1 for completely ordered groups, and show that the properties of this modification are the same as those of the original method. The advantage of this modification is that it generalizes naturally to partially ordered groups.
Complete orders

Review of the original Yuan-Chappell method
In Yuan and Chappell, 1 there are J dose levels under consideration, and the goal of the study is to find the ''maximum tolerated dose'' (MTD) in each of G risk groups. By definition, the MTD in group g is the highest dose under consideration that can be administered to patients in that group with an ''acceptable level'' of toxicity. ''Acceptable'' toxicity means limiting the proportion of patients in that group who experience a sufficiently severe, protocol-specified adverse event, usually called a ''dose-limiting toxicity'' (DLT). With cytotoxic agents, it is generally assumed that regardless of the group, the greater the dose administered, the greater the probability that a patient will experience a DLT.
The isotonic regression continual reassessment method proposed in Yuan and Chappell 1 is built on the continual reassessment method. 17 Originally proposed for a single risk group, the continual reassessment method assigns doses adaptively, with the dose for the current patient determined by the observed toxicities and dose allocations from the prior patients on the trial. Specifically, at any point in the trial, we have observed n j patients on dose level j, j = 1, . . . , J and among these patients, we have observed Y j patients experiencing a DLT. The number of patients with a DLT on dose level j, Y j , is distributed as independent Bin(n j , p j ), where p j is the probability that a patient will experience a DLT, given dose level j. The continual reassessment method uses a working model (1) for the p j
where 0\c 1 \c 2 \ Á Á Á \c J \1 are pre-specified constants, often referred to as the ''skeleton'' values and a is a scalar parameter. The parametrization exp(a) ensures that the probability of toxicity increases in dose for all À'\a\'. Advice on choosing skeleton values is given in Lee and Cheung. 18 With these specifications, at any point in the trial, the likelihood from the previously observed DLTs and dose allocations is
Current estimates of the DLT probabilities arê p j = c exp (â) j , where (â) is found by maximizing equation (2) as a function of a. Based on the current estimates, the next patient is assigned to the dose level jÃ with the smallest value of D(p j , u), where D(u, v) is a prespecified measure of distance, usually quadratic distance, between u and v. The parameter u is a target toxicity probability specified prior to the trial. The process of updating a and allocating patients to doses continues until a pre-specified number of patients have been observed. At the end of the study, the MTD is taken to be the dose that the next patient would have received had the trial not ended.
Yuan and Chappell 1 generalize the continual reassessment method to G completely ordered groups, where by convention, group 1 is the lowest risk group and patient in group G have the highest risk of a DLT. At any point in the trial, within group g, we have observed n gj patients allocated to dose level j and of these, Y gj patients have experienced a DLT. Assuming skeleton values 0\c 1 \c 2 \ Á Á Á \c J \1, the working model for the probability p gj that a patient in risk group g, given dose level j, experiences a DLT is given by
for j = 1, . . . , J and g = 1, . . . , G. The likelihood as a function of (a 1 , a 2 , . . . , a G ) is
Estimates (â 1 ,â 2 , . . . ,â G ) can be found by maximizing equation (4), and from these, we can obtain the current estimates of p gjp
The skeleton values and the working model guarantee that within groups, the estimated probabilities of toxicity increase with dose. Across groups, however, there may be ''reversals,'' meaning that at a given dose, the probability of a DLT is estimated to be greater in a lower risk group than in a higher risk group. To eliminate these reversals, Yuan and Chappell 1 create estimatesp Ã gj by applying the two-way isotonic regression procedure of Robertson et al. 2 to the model-based estimates,p gj , from equation (5) . The two-way isotonic regression estimation is an iterative process of adjusting the model-based estimates within rows and within columns to guarantee that the estimated probabilities of a DLT have no reversals, that is, the estimates are nondecreasing within rows and within columns. As in the original continual reassessment method, if the next patient is from group g, that patient is assigned the dose level with the ''isotonized'' estimate closest to the target toxicity probability, u, using a quadratic distance measure. The process of estimation and allocation continues until a pre-specified number of patients have been observed in each group.
A modification
As in the original Yuan and Chappell 1 method, we obtain the estimateâ = (â 1 ,â 2 , . . . ,â G ) by maximizing equation (4), and we let v j (â) denote the j th diagonal element of the observed information matrix based on the log of the likelihood (4) evaluated atâ. Instead of estimating the group-dose DLT probabilities from the model and using two-way isotonic regression, we apply the estimation procedure of Hwang and Peddada 16 toâ = (â 1 ,â 2 , . . . ,â G ) using weights 1 v j (â) to obtain estimates subjected to the following restriction
We denote the resulting estimates bŷ a HP = (â HP 1 ,â HP 2 . . . ,â HP G ), which satisfŷ
After ''isotonizing'' the estimates, we compute estimates of the probabilities of a DLT for dose d in group ĝ
Within groups, the estimated probabilities of a DLT increase with dose and for a fixed dose, the probabilities increase across groups. While Hwang and Peddada 16 provide a general estimation procedure for parameters subjected to partial orders, in the case of a complete order, the estimation procedure is identical to using isotonic regression on Àâ = ( Àâ 1 , Àâ 2 , . . . , Àâ G ) using weights 1 v j (â ), as in Robertson et al. 2 We would argue that this is a simpler method than the original to avoid reversals in the DLT probability estimates. In general, the number of groups is small, and the modification requires isotonic regression of only a small number of parameters. In order to make sure we have finite estimatesâ g , we use a pseudo-data prior as in Whitehead and Brunier 19 or Legedza and Ibrahim. 20 with total weight equal to one observation per group.
Comparing the original and the modification using a family of dose-toxicity curves
We denote the true MTD in group g by MTD g . With G groups and J dose levels under consideration, complete ordering of the groups implies that
We generated two scenarios for each of the possible configurations of the MTDs consistent with equation (9) . Table 1 lists the number of such configurations for three or four groups and four or six dose levels. Letting g = (g 1 , g 2 , g 3 ) denote one of these configurations; we generated group-dose toxicity probabilities p gj , g = 1, . . . , G and j = 1, . . . , J starting from group 1. We define p g, 0 = 0 and p 0, j = 0. In group g, for j = g g , we set p g, j = u. To generate probabilities for j 6 ¼ g g , we define ''Lower'' to equal max p gÀ1, j , p g, jÀ1 È É . For j\g g , we define ''Upper'' to equal the target, u and for j.g g , we define Upper to equal 1. With these definitions, we sequentially generated the true group-dose toxicity probabilities, p g, j as p g, j = Lower + (Upper À Lower) b (1, 4) where b (1, 4) are independently generated b-distributed random variables with mean 0.2 and variance 0.0267. This method of generating the group-dose toxicity probabilities guarantees that the resulting probabilities will follow the complete order.
For each scenario, we simulated 1000 trials with either a total of 36 or 54 patients, and either equal or unequal group probabilities. For three groups, the group probabilities were equal to 0.45, 0.40, and 0.15 to match the approximate group proportions in Innocenti et al. [8] For four groups, the group probabilities were chosen to be equal to 0.4, 0.3, 0.2, and 0.1. For each combination of sample size and group probabilities, we computed for both the original and the modified methods, the ''percent correct selection,'' defined as the proportion of times that the method correctly identifies the MTD in each group. We also computed the ''accuracy index'' of Cheung 21 within groups. Figure 1 displays the distribution of differences in the percent correct selection, modified minus original, and Figure 2 displays the distribution of differences in the accuracy index. The figures show a small difference between the original and the modified methods with, in general, the percent correct selection and the accuracy index with the original method greater than for the modification.
Partial orders
The results of the previous section indicate that for complete orders, applying order-restricted estimation methods toâ = (â 1 ,â 2 , . . . ,â G ), found by maximizing equation (4), has similar properties to the original design proposed by Yuan and Chappell. 1 By usingâ, however, the extension to partially ordered groups is straightforward. Table 2 lists a number of partial orders that could be encountered in three or four groups, along with the corresponding order restrictions satisfied by the Hwang and Peddada 16 estimates.
We use the study in Innocenti et al. 8 to illustrate the performance of this method. In this study, there were five dose levels of irinotecan, and patients were stratified by the *1/*1, *1/*28, and *28/*28 genotypes. This is an example of the first ordering in Table 2 ; patients with the *28/*28 genotype were expected to have a greater risk of severe neutropenia than either of the other genotypes. Of the 68 patients enrolled, 31 (46%) were in genotype *1/*1, 28 (41%) had genotype *1/*1, and 9 (13%) were in the *28/*28 group. In the complete order setting, we had randomly generated two scenarios for each of the 35 possible MTD configurations consistent with the complete order. To convert this to a partial order, we randomly chose one of the two scenarios for each of the possible MTD configurations, and interchanged the probabilities associated with the *1/*1 and *1/*28 groups. The other scenario in the pair was left unchanged. For each scenario, we simulated 1000 trials of 36, 54, and 72 patients under the assumption that each of the genotypes occur with probability 1/3 in the population. We also simulated trials under the assumption that the population proportions are 45% for genotype *1/*1, 40% for genotype *1/*28, and 15% for genotype *28/*28, similar to those observed in Innocenti et al. 8 The average percent correct selection and accuracy index values are given in Table 3 . We do not have a method to compare these results, but we can note that these values are comparable to the averages for the 3 3 5 case displayed in Figures 1 and 2 . As expected, the values are lower for the partial order, where there is less information about the groups than for the complete order.
An example of the dose allocations is given in Table  4 and is plotted in Figure 3 as in O'Quigley. 22 In this plot, open circles are patients who do not experience a DLT and closed circles represent DLTs. This trial was simulated based on the results in Innocenti et al. 8 Unequal group probabilities of 0.45, 0.40, and 0.15 were used, with toxicity probabilities of (0:005, 0:02, 0:03, 0:2, 0:33) in group 1, (:005, :02, 0:20, 0:30, 0:40) in group 2, and (0:20, 0:35, 0:50, 0:60, 0:70) in group 3. 2  3  2  0  3  1  2  0  4  2  3  0  5  1  3  0  6  3  3  0  7  1  4  0  8  3  4  1  9  3  2  0  10  2  3  0  11  1  4  0  12  2  4  1  13  1  5  0  14  3  2  1  15  3  1  0  16  3  1  0  17  1  5  0  18  2  2  0  19  1  5  1  20  3  2  1  21  2  2  0  22  1  4  0  23  3  1  0  24  3  1  1  25  3  1  0  26  1  5  0  27  3  1  0  28  2  3  0  29  1  5  0  30  3  1  0  31  3  1  0  32  1  5  0  33  2  3  0  34  2  3  0  35  3  1  1  36  2  4 1 The final recommendation for this example trial is level 5 in group 1, level 3 in group 2, and level 1 in group 3.
Summary and future directions
This article presents a modification of the Yuan and Chappell 1 method that can be applied for completely or partially ordered groups. For complete orders, the simulation results suggest that the properties of the modified estimates are similar to those originally proposed by Yuan and Chappell. With a known ordering between two groups, Conaway and Wages 15 show that the original method has excellent properties for 6 or 8 dose levels. The modification applies the Hwang-Peddada estimation method to the estimated parameters in the one-parameter model continual reassessment method. 17 While the method of Hwang and Peddada 16 is computationally simple, and produces estimates with good statistical properties, it is not a well-known algorithm. As an alternative, we are exploring the use of laying out multiple complete orders consistent with the partial order, and using model selection as in Wages et al. 23 to estimate which complete order is most consistent with the accumulated data. For example, if the partial order on the parameters wasâ HP 1 !â HP 3 andâ HP 2 !â HP 3 , we would postulate that eitherâ HP 1 !â HP 2 !â HP 3 orâ HP 2 !â HP 1 !â HP 3 .
There are several well-known algorithms, such as the pool-adjacent-violators algorithm (PAVA) or the minimum lower sets algorithm 2 that would produce estimates subjected to each of these complete orders. Once the ordered estimates are computed, we would estimate the dose-toxicity probabilities using the set of ordered estimates that yields the larger value of equation (4). Further work is needed on the properties of this alternative method. Additional research is also needed on calibrating the pseudo-data to ensure that dose escalation does not occur too rapidly early in the trial. An alternative is to do a two-stage design as in O'Quigley and Paoletti, 10 where the first stage is a rule-based design that follows the known orderings among the groups. The modeling stage of our modification of Yuan and Chappell 1 would begin only after heterogeneity in responses is observed in each of the groups.
